New data at the European Cystic Fibrosis Conference demonstrating significant benefits of treatment with Trikafta(elexacaftor/tezacaftor/ivacaftor and ivacaftor).- Vertex.

Data from a randomized, double-blind, Phase III study (abstract WS06.04) demonstrated that people with CF who have rare, non-F508del mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene responsive to Trikafta in vitro demonstrated clinical benefit from receiving Trikafta. Compared to placebo, lung function improved by 9.2 percentage points as measured by ppFEV1, CFTR function improved (as measured by mean sweat chloride concentration reductions of 28.3 mmol/L), and pulmonary exacerbations were reduced by 72% per year. Safety and tolerability were generally consistent with the established safety profile of Trikafta.

Vertex also presented the interim analysis (IA) of a Kaftrio plus ivacaftor from 2020-21 in Germany (abstract WS01.04) . The ongoing five-year post-authorization study is the largest real-world study of people with CF treated with Trikafta to date, including more than 16,000 people with CF from the U.S. Cystic Fibrosis Foundation Patient Registry (CFFPR) and approximately 3,000 people with CF from the German CF Registry. The IA showed clinically meaningful, disease-modifying benefits for Trikafta/Kaftrio, including a 76% and 70% reduction in the cumulative annual rate of pulmonary exacerbations in the U.S. and in Germany, respectively, compared to the year prior to Trikafra/ Kaftrio treatment. In addition, there was a 62% lower rate of death in the U.S. and 84% lower in Germany; and an 86% lower rate of lung transplant in the U.S. and 96% lower in Germany compared to the 2019 U.S. CFFPR and German CF Registry populations (pre-Trikafta/KAFTRIO®). No new safety concerns were identified.